Literature DB >> 16951220

Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype.

Dang M Nguyen1, Kathy Sam, Anna Tsimelzon, Xiaoxian Li, Helen Wong, Syed Mohsin, Gary M Clark, Susan G Hilsenbeck, Richard M Elledge, D Craig Allred, Peter O'Connell, Jenny C Chang.   

Abstract

PURPOSE: Inflammatory breast cancer (IBC) is associated with very poor prognosis. The aims of this study are (a) to prospectively identify differential gene expression patterns associated with IBC and (b) to confirm these pathways using tissue arrays. EXPERIMENTAL
DESIGN: For gene expression analysis, IBC (n=14) was clinically defined as rapid-onset cancer associated with erythema and skin changes, whereas non-IBC patients (n=20) had stage III breast cancers, and cDNA analysis was carried out using the Affymetrix (Santa Clara, CA) HG-U133A microarrays. Tissue arrays were constructed from paraffin-embedded material, and the molecular phenotype of 75 IBC was compared with results from>2,000 non-IBC.
RESULTS: Gene expression analyses indicated that IBC has higher expression of genes associated with increased metabolic rate, lipid signaling, and cell turnover relative to non-IBC tumors. Consistent with the expression analysis, IBC had statistically higher Ki-67 (93% versus 11%; P<0.001). BAX expression, reflecting increased apoptosis and cell turnover, was significantly uniformly higher in almost all IBC (98% versus 66%; P<0.05), whereas the expression of Bcl-2 was not significantly different. IBC tumors were more likely to be steroid hormone receptor negative (estrogen receptor, 49% versus 30%; P=0.002; progesterone receptor, 68% versus 42%; P=0.001). The expression of tyrosine kinases was not significantly different. E-cadherin was found to be expressed in 87% of IBC, whereas the expression p53 was not significantly different.
CONCLUSION: This study is one of the largest molecular analyses of IBC. Both IBC and non-IBC are genetically heterogeneous with consistent differences in the molecular phenotype of IBC.

Entities:  

Mesh:

Year:  2006        PMID: 16951220     DOI: 10.1158/1078-0432.CCR-05-2248

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  Trastuzumab in inflammatory breast cancer.

Authors:  R S Mehta; T Schubbert; K Kong
Journal:  Ann Oncol       Date:  2008-08-18       Impact factor: 32.976

Review 3.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

4.  MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer.

Authors:  Lei Huo; Yan Wang; Yun Gong; Savitri Krishnamurthy; Jing Wang; Lixia Diao; Chang-Gong Liu; Xiuping Liu; Feng Lin; William F Symmans; Wei Wei; Xinna Zhang; Li Sun; Ricardo H Alvarez; Naoto T Ueno; Tamer M Fouad; Kenichi Harano; Bisrat G Debeb; Yun Wu; James Reuben; Massimo Cristofanilli; Zhuang Zuo
Journal:  Mod Pathol       Date:  2016-02-26       Impact factor: 7.842

5.  Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.

Authors:  Takayuki Iwamoto; Giampaolo Bianchini; Yuan Qi; Massimo Cristofanilli; Anthony Lucci; Wendy A Woodward; James M Reuben; Junji Matsuoka; Yun Gong; Savitri Krishnamurthy; Vicente Valero; Gabriel N Hortobagyi; Fredika Robertson; W Fraser Symmans; Lajos Pusztai; Naoto T Ueno
Journal:  Breast Cancer Res Treat       Date:  2010-12-09       Impact factor: 4.872

6.  X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.

Authors:  Katherine M Aird; Rami B Ghanayem; Sharon Peplinski; Herbert K Lyerly; Gayathri R Devi
Journal:  Mol Cancer Ther       Date:  2010-04-20       Impact factor: 6.261

7.  Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Authors:  Jennifer L Allensworth; Myron K Evans; François Bertucci; Amy J Aldrich; Richard A Festa; Pascal Finetti; Naoto T Ueno; Rachid Safi; Donald P McDonnell; Dennis J Thiele; Steven Van Laere; Gayathri R Devi
Journal:  Mol Oncol       Date:  2015-02-21       Impact factor: 6.603

8.  Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival.

Authors:  F Bertucci; N T Ueno; P Finetti; P Vermeulen; A Lucci; F M Robertson; M Marsan; T Iwamoto; S Krishnamurthy; H Masuda; P Van Dam; W A Woodward; M Cristofanilli; J M Reuben; L Dirix; P Viens; W F Symmans; D Birnbaum; S J Van Laere
Journal:  Ann Oncol       Date:  2013-12-02       Impact factor: 32.976

Review 9.  Three-dimensional culture systems in cancer research: Focus on tumor spheroid model.

Authors:  Sritama Nath; Gayathri R Devi
Journal:  Pharmacol Ther       Date:  2016-04-08       Impact factor: 12.310

10.  Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.

Authors:  Jason A Zell; Walter Y Tsang; Thomas H Taylor; Rita S Mehta; Hoda Anton-Culver
Journal:  Breast Cancer Res       Date:  2009-02-19       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.